Non-Covalent Binding of Disodium Disuccinate Astaxanthin to the Catalytic Site of Phosphodiesterase 5A: A Molecular Modeling Study

Eszter, Hazai; Zsolt, Bikadi; Ferenc, Zsila; Samuel,F. Lockwood

Non-Covalent Binding of Disodium Disuccinate Astaxanthin to the Catalytic Site of Phosphodiesterase 5A: A Molecular Modeling Study

Author(s): Eszter Hazai, Zsolt Bikadi, Ferenc Zsila, Samuel F. Lockwood

Affiliation:

Journal Name: Letters in Drug Design & Discovery

Volume 4 , Issue 2 , 2007

DOI : 10.2174/157018007779422497

Journal Home

Abstract:

Phosphodiesterases are clinical targets for congestive heart failure, erectile dysfunction and inflammation. Intake of carotenoids decreases the risk of cardiovascular and inflammatory diseases. Therefore, phosphodiesterase binding of the carotenoid derivative disodium disuccinate astaxanthin (Cardax) was investigated using molecular modeling methods. Cardax was predicted to bind to PDE5A at the catalytic site.

Keywords: Astaxanthin, Cardax, Carotenoids, Disodium disuccinate astaxanthin, Docking, Phosphodiesterase 5A

Rights & Permissions Print Export Cite as

Letters in Drug Design & Discovery

Title: Non-Covalent Binding of Disodium Disuccinate Astaxanthin to the Catalytic Site of Phosphodiesterase 5A: A Molecular Modeling Study

VOLUME: 4 ISSUE: 2

Author(s):Eszter Hazai, Zsolt Bikadi, Ferenc Zsila and Samuel F. Lockwood

Affiliation:Virtua Drug Ltd, Csalogany u. 4c H-1015 Budapest, Hungary.

Keywords:Astaxanthin, Cardax, Carotenoids, Disodium disuccinate astaxanthin, Docking, Phosphodiesterase 5A

Abstract: Phosphodiesterases are clinical targets for congestive heart failure, erectile dysfunction and inflammation. Intake of carotenoids decreases the risk of cardiovascular and inflammatory diseases. Therefore, phosphodiesterase binding of the carotenoid derivative disodium disuccinate astaxanthin (Cardax) was investigated using molecular modeling methods. Cardax was predicted to bind to PDE5A at the catalytic site.

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Eszter Hazai, Zsolt Bikadi, Ferenc Zsila and Samuel F. Lockwood, “ Non-Covalent Binding of Disodium Disuccinate Astaxanthin to the Catalytic Site of Phosphodiesterase 5A: A Molecular Modeling Study”, Letters in Drug Design & Discovery (2007) 4: 128. https://doi.org/10.2174/157018007779422497

DOI https://doi.org/10.2174/157018007779422497	Print ISSN 1570-1808
Publisher Name Bentham Science Publisher	Online ISSN 1875-628X

About this journal

Article Details

VOLUME: 4
ISSUE: 2
Year: 2007

Page: [128 - 136]
Pages: 9
DOI: 10.2174/157018007779422497
Price: $65

Article Metrics

PDF: 1

Most Downloaded Article(s)

An Improved Preparation of (R)-3-Aminobutanol, a Key Intermediate for the Synthesis of Dolutegravir Sodium
Letters in Drug Design & Discovery
Meet Our Editorial Board Member
Letters in Drug Design & Discovery
Synthesis of New Bis-pyrazolines Endowed with Potent Antifungal Activity against Candida albicans and Aspergillus niger
Letters in Drug Design & Discovery
3,4,5-Trisubstituted-1,2,4-triazole Derivatives as Antiproliferative Agents: Synthesis, In vitro Evaluation and Molecular Modelling
Letters in Drug Design & Discovery
Synthesis of the Neurotransmitter 4-Aminobutanoic Acid (GABA) from Diethyl Cyanomalonate
Letters in Drug Design & Discovery
Comparison in the Glucose Response of Flexible Liposomes Loaded with Insulin with the Addition of Different Surfactants in an Experimental Diabetes Model
Letters in Drug Design & Discovery
Lapatinib as a Dual Tyrosine Kinase Inhibitor Unexpectedly Activates Akt in MDA-MB-231 Triple-Negative Breast Cancer Cells
Letters in Drug Design & Discovery
Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins
Letters in Drug Design & Discovery
Development of Phthalimide-Donepezil Hybrids as Potent Multitarget- Directed Ligands for the Treatment of Alzheimer’s Disease
Letters in Drug Design & Discovery
Design, Synthesis, In vitro and In silico Evaluation of New Hydrazonebased Antitumor Agents as Potent Akt Inhibitors
Letters in Drug Design & Discovery